Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 fluorescence-guided surgery feasibility study in colorectal brain metastases
NL-OMON56091Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sgm-101 in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoint: Resection margin concordance. Started Apr 2024; status: recruiting.
02
Drugs
sgm-101
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON56091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56091.